A Comparative Evaluation of a Novel Vaccine in APP/PS1 Mouse Models of Alzheimer’s Disease

Figure 2

Comparative effect of EB101 vaccine on beta amyloid deposits. Comparative photomicrographs of Aβ immunoreactivity were taken in the hippocampus ((a)–(e), (k)–(o)) and cortical ((f)–(j), (p)–(t)) brain regions of transgenic mice with different treatments before Aβ plaques development, preventive treatment ((a)–(j)) and after the Aβ plaques developed, therapeutic treatment ((k)–(t)). Preventive treatment: transverse brain sections of 11-month-old mice show reduced number of Aβ deposits in the dentate gyrus, hippocampal subregion CA1 (a), and entorhinal cortex (f) following EB101 vaccine immunization (Group A), contrasting with the numerous Aβ immunoreactive plaques in the correspondent mouse brain sections of Groups B ((b), (g)), C ((c), (h)), D ((d), (i)), and E ((e), (j)). Immunoreactive Aβ in the brain sections of wild-type (WT) mice is absent (inserts in panels (e), (o)). Therapeutic treatment: transverse brain sections of 18-month-old mice are shown in panels (k)–(t). Treatment with EB101 almost completely cleared Aβ load in the dentate gyrus and reduced notably the density in hippocampal subregion CA1 (k) and entorhinal cortex (p) compared to the same areas of mouse Groups B ((l), (q)), C ((m),(r)), D ((n), (s)), and E ((o), (t)), as determined by number of plaques and staining intensity area. Scale bar: 100 μm.